

MEDNAX, INC.
RECONCILIATION OF INCOME FROM CONTINUING OPERATIONS
TO ADJUSTED EBITDA FROM CONTINUING OPERATIONS ATTRIBUTABLE TO MEDNAX, INC.
(in thousands)
(Unaudited)

	Three Months Ended September 30,	
	2021	2020
Income (loss) from continuing operations attributable to Mednax, Inc.	\$ 31,847	\$ (2,652)
Interest expense	17,595	27,250
Gain on sale of building	-	-
Income tax provision	11,594	6,677
Depreciation and amortization expense	8,151	7,195
Transformational and restructuring related expenses	4,232	34,291
Adjusted EBITDA from continuing operations attributable to Mednax, Inc.	<u>\$ 73,419</u>	<u>\$ 72,761</u>

	Nine Months Ended September 30,	
	2021	2020
Income (loss) from continuing operations attributable to Mednax, Inc.	\$ 67,732	\$ (14,067)
Interest expense	52,119	83,180
Gain on sale of building	(7,280)	-
Loss on early extinguishment of debt	14,532	-
Income tax provision	14,002	10,859
Depreciation and amortization	24,288	20,749
Transformational and restructuring related expenses	19,042	60,846
Adjusted EBITDA from continuing operations attributable to Mednax, Inc.	<u>\$ 184,435</u>	<u>\$ 161,567</u>